FDA Lifts Clinical Hold of Pluristem Therapeutics Inc's Phase II Intermittent Claudication Study
Pluristem Therapeutics Inc, a leading developer of placenta-based cell therapies, announced today that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on the Company's U.S. Phase II Intermittent Claudication (IC) study (IND 15038) on June 4, 2013.
View full press release